Matthew Meyerson

Matthew Meyerson

Top Cited Scholar 2026
Auto-generated profile, based on publicly available information

Matthew Meyerson

Broad Institute of MIT and Harvard, Cambridge, USA

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 August 2013 in Nature
Verified
Journal Article
Open access
PDF file
AIAustralian Pancreatic Cancer Genome Initiative
Australian Pancreatic Cancer Genome Initiative
LALudmil B. Alexandrov
Ludmil B. Alexandrov
ICICGC Breast Cancer Consortium
ICGC Breast Cancer Consortium
ICICGC MMML-Seq Consortium
ICGC MMML-Seq Consortium
IPICGC PedBrain
ICGC PedBrain
MSMichael R. Stratton
Michael R. Stratton
All cancers are caused by somatic mutations; however, understanding of the biological processes generating these mutations is limited. The catalogue of somatic mutations from a cancer genome bears the signatures of the mutational processes that have been operative. Here we analysed 4,938,362 mutations from 7,042 cancers and extracted more than 20 distinct mutational signatures. Some are present in many cancer types, notably a signature attributed to the APOBEC family of cytidine deaminases, whereas others are confined to a single cancer class. Certain signatures are associated with age of the patient at cancer diagnosis, known mutagenic exposures or defects in DNA maintenance, but many are of cryptic origin. In addition to these genome-wide mutational signatures, hypermutation localized to small genomic regions, ‘kataegis’, is found in many cancer types. The results reveal the diversity of mutational processes underlying the development of cancer, with potential implications for understanding of cancer aetiology, prevention and therapy.

16 June 2013 in Nature
Verified
Journal Article
Open access
PDF file
MLMichael S. Lawrence
Michael S. Lawrence
PSPetar Stojanov
Petar Stojanov
PPPaz Polak
Paz Polak
GKGregory V. Kryukov
Gregory V. Kryukov
KCKristian Cibulskis
Kristian Cibulskis
GGGad Getz
Gad Getz
As the sample size in cancer genome studies increases, the list of genes identified as significantly mutated is likely to include more false positives; here, this problem is identified as stemming largely from mutation heterogeneity, and a new analytical methodology designed to overcome this problem is described. Cancer genomic approaches have identified scores of genes responsible for the initiation and progression of cancer. But as the sample sizes increase, the list of putatively significant genes identified by current analytical methods continues to grow and is likely to include many false positives. This study shows that this situation stems largely from mutational heterogeneity and presents a novel methodology, MutSigCV, that overcomes the problem by incorporating mutational heterogeneity into the analysis. Application of MutSigCV to more than 3,000 tumour samples from 27 different tumour types shows that mutation frequencies vary more than 1,000-fold between extreme samples both between and within tumour types. And when applied to a data set on lung cancer, MutSigCV reduced the list of significantly mutated genes from 450 to a more manageable 11, most of them previously reported to be mutated in squamous cell lung cancer. Major international projects are underway that are aimed at creating a comprehensive catalogue of all the genes responsible for the initiation and progression of cancer1,2,3,4,5,6,7,8,9. These studies involve the sequencing of matched tumour–normal samples followed by mathematical analysis to identify those genes in which mutations occur more frequently than expected by random chance. Here we describe a fundamental problem with cancer genome studies: as the sample size increases, the list of putatively significant genes produced by current analytical methods burgeons into the hundreds. The list includes many implausible genes (such as those encoding olfactory receptors and the muscle protein titin), suggesting extensive false-positive findings that overshadow true driver events. We show that this problem stems largely from mutational heterogeneity and provide a novel analytical methodology, MutSigCV, for resolving the problem. We apply MutSigCV to exome sequences from 3,083 tumour–normal pairs and discover extraordinary variation in mutation frequency and spectrum within cancer types, which sheds light on mutational processes and disease aetiology, and in mutation frequency across the genome, which is strongly correlated with DNA replication timing and also with transcriptional activity. By incorporating mutational heterogeneity into the analyses, MutSigCV is able to eliminate most of the apparent artefactual findings and enable the identification of genes truly associated with cancer.

1 October 2013 in Cell
Verified
Journal Article
Closed access
CBCameron W. Brennan
Cameron W. Brennan
RVRoel G.W. Verhaak
Roel G.W. Verhaak
AMAaron McKenna
Aaron McKenna
BCBenito Campos
Benito Campos
HNHoutan Noushmehr
Houtan Noushmehr
RMRoger McLendon
Roger McLendon

28 April 2011 in Genome Biology
Verified
Journal Article
Open access
PDF file
CMCraig H Mermel
Craig H Mermel
SSSteven E Schumacher
Steven E Schumacher
BHBarbara Hill
Barbara Hill
MMMatthew L Meyerson
Matthew L Meyerson
RBRameen Beroukhim
Rameen Beroukhim
GGGad Getz
Gad Getz
We describe methods with enhanced power and specificity to identify genes targeted by somatic copy-number alterations (SCNAs) that drive cancer growth. By separating SCNA profiles into underlying arm-level and focal alterations, we improve the estimation of background rates for each category. We additionally describe a probabilistic method for defining the boundaries of selected-for SCNA regions with user-defined confidence. Here we detail this revised computational approach, GISTIC2.0, and validate its performance in real and simulated datasets.

5 January 2014 in Nature
Verified
Journal Article
Open access
PDF file
MLMichael S. Lawrence
Michael S. Lawrence
PSPetar Stojanov
Petar Stojanov
CMCraig H. Mermel
Craig H. Mermel
JRJames T. Robinson
James T. Robinson
LGLevi A. Garraway
Levi A. Garraway
GGGad Getz
Gad Getz
Although a few cancer genes are mutated in a high proportion of tumours of a given type (>20%), most are mutated at intermediate frequencies (2–20%). To explore the feasibility of creating a comprehensive catalogue of cancer genes, we analysed somatic point mutations in exome sequences from 4,742 human cancers and their matched normal-tissue samples across 21 cancer types. We found that large-scale genomic analysis can identify nearly all known cancer genes in these tumour types. Our analysis also identified 33 genes that were not previously known to be significantly mutated in cancer, including genes related to proliferation, apoptosis, genome stability, chromatin regulation, immune evasion, RNA processing and protein homeostasis. Down-sampling analysis indicates that larger sample sizes will reveal many more genes mutated at clinically important frequencies. We estimate that near-saturation may be achieved with 600–5,000 samples per tumour type, depending on background mutation frequency. The results may help to guide the next stage of cancer genomics.

1 October 2014 in Cell
Verified
Journal Article
Open access
NANishant Agrawal
Nishant Agrawal
RARehan Akbani
Rehan Akbani
BAB. Arman Aksoy
B. Arman Aksoy
AAAdrian Ally
Adrian Ally
HAHarindra Arachchi
Harindra Arachchi
LZLihua Zou
Lihua Zou
Papillary thyroid carcinoma (PTC) is the most common type of thyroid cancer. Here, we describe the genomic landscape of 496 PTCs. We observed a low frequency of somatic alterations (relative to other carcinomas) and extended the set of known PTC driver alterations to include EIF1AX, PPM1D, and CHEK2 and diverse gene fusions. These discoveries reduced the fraction of PTC cases with unknown oncogenic driver from 25% to 3.5%. Combined analyses of genomic variants, gene expression, and methylation demonstrated that different driver groups lead to different pathologies with distinct signaling and differentiation characteristics. Similarly, we identified distinct molecular subgroups of BRAF-mutant tumors, and multidimensional analyses highlighted a potential involvement of oncomiRs in less-differentiated subgroups. Our results propose a reclassification of thyroid cancers into molecular subtypes that better reflect their underlying signaling and differentiation properties, which has the potential to improve their pathological classification and better inform the management of the disease.